AZ/Oxford University’s COVID-19 vaccine shows average efficacy of 70%
Effectiveness ranges from 62% to 90% depending on dosing regimen
Read More
Tag: AZD1222
AZ resumes trial of COVID-19 vaccine
The move follows a green light by the UK’s MHRA
Read More
AZ pauses COVID-19 vaccine trials for safety review
Data will be reviewed after a study volunteer experienced an unexpected illness
Read More
PhIII US trial for AZ’ coronavirus vaccine
Clinical development of AZD1222 is progressing globally with late-stage clinical trials ongoing in the UK, Brazil and South Africa
Read More
AZ seals deal with EC for coronavirus vaccine supply
Up to 400 million doses of AZD1222 will be supplied to EU member states under the deal
Read More
AZ signs deal with Europe’s IVA for coronavirus vaccine supply
The drug giant has agreed to supply 400 million doses of the vaccine under the deal
Read More
Oxford Biomedica and VMIC announce collaboration
The five-year deal will see the parties work collaboratively to facilitate the manufacture of viral vector based vaccines
Read More
AZ ramps up supply capacity for COVID-19 vaccine
Agreements with CEPI and Gavi and the Serum Institute of India will bring vaccine to low and middle-income countries and beyond, the firm said
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
